The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population‐based study in the Netherlands, 1989–2018

Maas, Carolien C. H. M.; Klaveren, David van; Ector, Geneviève I C G; Posthuma, Eduardus F M; Visser, Otto; Westerweel, Peter E.; Janssen, Jeroen; Blijlevens, Nicole M A; Dinmohamed, Avinash G.

doi:10.1111/bjh.17989

Cited by 15 publications

(16 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, Maas et al published a retrospective report on the evolution of life expectancy (LE) and life years lost (LYLs) of patients with chronic myeloid leukaemia (CML) in the Netherlands over the last 30 years. 1 Together with a previous one from Sweden, this is the second such report from a western country suggesting that the introduction of breakpoint cluster region-Abelson (BCR-ABL) tyrosine kinase inhibitors (TKIs) after 2000 led to LE similar to that in the general population. 2 However, such real-world clinical outcomes may differ significantly between countries because of the variable demographic structure of the population and accessibility to health care services.…”

Section: Dynamic Trends In Life Expectancy and Life Years Lost Over F...mentioning

confidence: 63%

Dynamic trends in life expectancy and life years lost over five decades in patients from the SEER database with chronic myeloid leukaemia

Shivarov

Grigorova

2022

Br J Haematol

View full text Add to dashboard Cite

Section: Dynamic Trends In Life Expectancy and Life Years Lost Over F...mentioning

confidence: 63%

Dynamic trends in life expectancy and life years lost over five decades in patients from the SEER database with chronic myeloid leukaemia

Shivarov

Grigorova

2022

Br J Haematol

View full text Add to dashboard Cite

“…Four BCR::ABL1 TKIs are approved for frontline therapy: imatinib, dasatinib, bosutinib and nilotinib. All four produce near-normal quality of life and life expectancy provided patients comply with the treatment, are monitored optimally with minimal interruptions in therapy, and are managed appropriately at the earliest sign of true treatment resistance [ 8 – 13 ]. Imatinib is available as a generic drug in the United States (US), and at least one of the 15 available formulations is priced at about $500/year in the US (through Cost Plus Drugs, for example) [ 14 – 17 ].…”

Section: Frontline CML Therapymentioning

confidence: 99%

Management of chronic myeloid leukemia in 2023 – common ground and common sense

et al. 2023

View full text Add to dashboard Cite

With the improving knowledge of CML and its management, the goals of therapy need to be revisited to ensure an optimal use of the BCR::ABL1 TKIs in the frontline and later-line therapy of CML. In the frontline therapy of CML in the chronic phase (CML-CP), imatinib and the three second-generation TKIs (bosutinib, dasatinib and nilotinib) are associated with comparable survival results. The second-generation TKIs may produce earlier deep molecular responses, hence reducing the time to reaching a treatment-free remission (TFR). The choice of the second-generation TKI versus imatinib in frontline therapy is based on the treatment aims (survival, TFR), the CML risk, the drug cost, and the toxicity profile with respect to the patient’s comorbidities. The TKI dosing is more flexible than has been described in the registration trials, and dose adjustments can be considered both in the frontline and later-line settings (e.g., dasatinib 50 mg frontline therapy; dose adjusted schedules of bosutinib and ponatinib), as well as during an ongoing TKI therapy to manage toxicities, before considering changing the TKI. In patients who are not candidates for TFR, BCR::ABL1 (International Scale) transcripts levels <1% are acceptable, result in virtually similar survival as with deeper molecular remissions, and need not warrant a change of TKI. For patients with true resistance to second-generation TKIs or with the T315I gatekeeper mutation, the third-generation TKIs are preferred. Ponatinib should be considered first because of the cumulative experience and results in the CML subsets, including in T315I-mutated CML. A response-based dosing of ponatinib is safe and leads to high TKI compliance. Asciminib is a third-generation TKI with possibly a better toxicity profile, but lesser activity in T315I-mutated CML. Olverembatinib is another potent third-generation TKI with early promising results.

show abstract

“…All of these symptoms have implications on physical performance, emotional well-being, and health-related quality of life (HrQoL), and lead to work productivity impairments ( 1 , 6 , 7 ). Thanks to advances in diagnostics and therapy, many MPN pts have an almost normal life expectancy ( 8 , 9 ). Of note, myelofibrosis (MF) -primary or secondary- is often associated with a more severe disease course and decreased overall survival ( 10 ).…”

Section: Introductionmentioning

confidence: 99%

Anxieties, age and motivation influence physical activity in patients with myeloproliferative neoplasms - a multicenter survey from the East German study group for hematology and oncology (OSHO #97)

Felser

Rogahn²,

Coutre³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundPhysical activity (PA) is a non-pharmacological approach to alleviate symptom burden and improve health-related quality of life (HrQoL) in cancer patients (pts). Whether pts with myeloproliferative neoplasms (MPN) PA behavior changes due to symptom burden and/or knowledge of the putative beneficial effects of PA has not yet been investigated.MethodsWe performed a large questionnaire study in MPN pts. Self-reported PA behavior and potential influencing factors of 634 MPN pts were analyzed. Questionnaires were used to assess demographics, anxiety, severity of symptoms, HrQoL, current level of everyday and sports activities, and the level of information regarding the importance/possibilities of PA. According to their PA, the pts were assigned to the three groups: “inactive”, “non-targeted active”, and “sporty active” and compared with each other.ResultsKey findings are that in 73% of the pts, the disease had an impact on PA, with 30% of pts reducing their PA. The prevalence of anxieties (e.g., occurrence of thrombosis and bleeding) regarding PA was 45%. Sporty active pts had a lower symptom burden and better HrQoL (p ≤ 0.001) compared to the other groups. Inactive pts were significantly older and had a higher body mass index than sporty active pts. Inactive and non-targeted active pts felt less informed about the importance/possibilities of PA (p = 0.002).ConclusionOur results suggest that especially older and non-sporty MPN pts could benefit from motivational as well as disease-specific PA information. This study was registered at the German Registry of Clinical Trials, DRKS00023698.

show abstract

The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population‐based study in the Netherlands, 1989–2018

Cited by 15 publications

References 15 publications

Dynamic trends in life expectancy and life years lost over five decades in patients from the SEER database with chronic myeloid leukaemia

Dynamic trends in life expectancy and life years lost over five decades in patients from the SEER database with chronic myeloid leukaemia

Management of chronic myeloid leukemia in 2023 – common ground and common sense

Anxieties, age and motivation influence physical activity in patients with myeloproliferative neoplasms - a multicenter survey from the East German study group for hematology and oncology (OSHO #97)

Contact Info

Product

Resources

About